PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
2024年10月10日 - 5:04AM
PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a
surgical robotics company focused on advancing patient care by
developing transformative solutions in urology, today announced it
will report financial results for the third quarter of 2024 before
market open on Monday, October 28, 2024. The Company’s management
will host a corresponding conference call beginning at 8:00 a.m.
Eastern Time.
Investors interested in listening to the conference call may do
so by following one of the below links:
- Webcast link for interested listeners:
- https://edge.media-server.com/mmc/p/yhamkcsz
- Dial-in registration for sell-side research analysts:
-
https://register.vevent.com/register/BI271ff7de75a342d8941d642d1900ba40
Live audio of the webcast will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com. Each webcast will be available
for replay for at least 90 days after the event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic
Systems. The HYDROS Robotic System is the only AI-Powered, robotic
technology that delivers Aquablation therapy. PROCEPT BioRobotics
designed Aquablation therapy to deliver effective, safe, and
durable outcomes for males suffering from lower urinary tract
symptoms or LUTS, due to BPH that are independent of prostate size
and shape or surgeon experience. BPH is the most common prostate
disease and impacts approximately 40 million men in the United
States. The Company has developed a significant and growing body of
clinical evidence with over 150 peer-reviewed publications,
supporting the benefits and clinical advantages of Aquablation
therapy.
Investor Contact:Matt BacsoVP, Investor
Relations and Business
Operationsm.bacso@PROCEPT-BioRobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
過去 株価チャート
から 10 2024 まで 11 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
過去 株価チャート
から 11 2023 まで 11 2024